Vaccibody

Vaccibody rebrands as Nykode, and unveils big Regeneron partnership

Norwegian biotech Vaccibody has changed its name to Nykode Therapeutics, and celebrated its new identity with a sizeable deal with Regeneron to develop vaccines for cancer and infectious diseases. The Oslo-based company is getting $50 million upfront from Regeneron – split between cash and an equity investment – with another $875 million on the table …

Vaccibody rebrands as Nykode, and unveils big Regeneron partnership Read More »

Roche pays $200m for Vaccibody’s cancer vaccine drug

Roche’s Genentech unit has paid $200 million to develop an individualised cancer vaccine with Norwegian biotech Vaccibody, which focuses on targets known as neoantigens that spring up as tumours grow and mutate. The deal with the Oslo-based company is worth up to $715 million, with potential milestone payments worth up to $515 million on top …

Roche pays $200m for Vaccibody’s cancer vaccine drug Read More »